Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome

Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome. a 4-Week, Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase IV Trial

To assess the effectiveness of alverine citrate and simeticone on IBS symptoms according to the latest recommended design

Inclusion Criteria:

• male or female ambulatory patients, aged 18-75 years
• with IBS as defined by Rome III criteria

Exclusion Criteria:

• Functional bowel disorder other than IBS,
• Underlying cause for symptomatology, which excludes IBS diagnosis,
• Gastro-intestinal cancer or significant gastro-intestinal surgical background,
• Any acute/uncontrolled systemic pathology